Feasibility of endoscopic resection for superficial laryngopharyngeal cancer after radiotherapy
Hiroshi Ashizawa,Yoichi Yamamoto,Takashi Mukaigawa,Noboru Kawata,Yuki Maeda,Masao Yoshida,Tatsunori Minamide,Kinichi Hotta,Kenichiro Imai,Sayo Ito,Kazunori Takada,Junya Sato,Hirotoshi Ishiwatari,Hiroyuki Matsubayashi,Hiroyuki Ono
DOI: https://doi.org/10.1111/jgh.16789
2024-11-02
Journal of Gastroenterology and Hepatology
Abstract:Background and Aim We aimed to elucidate the feasibility of endoscopic resection (ER) for salvage and metachronous lesions following chemoradiotherapy (CRT) and radiotherapy (RT) for laryngopharyngeal cancer. Methods Consecutive patients who underwent ER for superficial laryngopharyngeal cancer between March 2005 and September 2022 were retrospectively reviewed and stratified into salvage (16 patients, 16 lesions), metachronous (18 patients, 27 lesions), and naïve RT (217 patients, 306 lesions) groups. Salvage lesions were residual or local recurrent after CRT, and metachronous lesions were second primary lesions in the irradiated field following complete response. Short‐term outcomes were evaluated, including R0 resection, en bloc resection, procedure time, adverse events, local recurrence rate, and clinical course. Results The en bloc resection rates were 88%, 93%, and 88%; R0 resection rates were 50%, 52%, and 56%; procedure times were 25, 27, and 25 min, in the salvage, metachronous, and naïve RT groups, none of which were significantly different among the three groups. Although adverse event rates tended to be higher in the salvage and metachronous groups than in the naïve RT group, the differences were not significant (18%, 15%, and 8%). The cumulative local recurrence rates at 2 years were 21%, 13%, and 6%, significantly higher in the salvage group than in the naïve RT group. The local control rates with ER alone were 94%, 93%, and 97%; none were significantly different among the three groups. Conclusion ER for salvage and metachronous superficial lesions can be safely performed, suggesting its acceptability as a minimally invasive treatment.
gastroenterology & hepatology